Background While up to 50% of patients with severe asthma have no evidence of allergy,
IgE has been linked to asthma, irrespective of atopic status. Omalizumab, an anti-IgE …

Background Omalizumab, a humanized anti-IgE monoclonal antibody, is reportedly an
effective treatment for severe allergic asthma. However, there have been few …

IgE molecules play a crucial role in allergic respiratory diseases and may cause chronic
airway inflammation in asthma through activation of effector cells via high-affinity (FcεRI) or …

Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the
treatment of severe allergic asthma. This drug inhibits allergic responses by binding to …

Aim. To evaluate the effectiveness of omalizumab in non-atopic asthma. Methods. Using
data from a multicenter registry of severe asthma, we evaluated and compared the clinical …

Rationale: For many patients with asthma, allergic airway inflammation is primarily a Th2-
weighted process; however, heterogeneity in patterns of inflammation suggests phenotypic …

Background Assessment of clinical outcomes in the real-world corroborates findings from
randomized controlled trials (RCTs). Objective This meta-analysis evaluated real-world data …

Different subsets of asthma patients may be recognized according to the exposure trigger
and the frequency and severity of clinical signs and symptoms. Regarding the exposure …

IgE is central to the pathophysiology of allergic asthma. Omalizumab, a humanized anti-IgE
mAb, specifically binds free IgE and interrupts the allergic cascade by preventing binding of …

Omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, is a
treatment option for patients with moderate to severe allergic asthma whose asthma is …